{"success":true,"data":{"pressRelease":{"id":"52346","rtpr_id":"nGNX7V3wxy","ticker":"SRTA","exchange":"NASDAQ","all_tickers":["SRTA"],"title":"Strata Acquires Louisville Perfusion Services","author":"Globe Newswire","published_at":"2026-06-02T13:00:03.844Z","article_body":"NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc.\n(Nasdaq: SRTA, “Strata” or the “Company”), today announced that it has\ncompleted the acquisition of Louisville Perfusion Services, Inc. (“LPS”),\na regional provider of perfusion and blood management services to cardiac\nsurgery programs in Kentucky.\n\n“The acquisition of Louisville Perfusion Services fits perfectly with our\nexisting customer base in Kentucky and Ohio, giving us a new strategic\nstronghold in the Midwest and Southern United States,” said Lou Verdetto,\nCEO of Strata’s Clinical Division. “More than just unlocking the ability\nto win new perfusion contracts in the region, LPS also expands the national\nfootprint of staff and equipment available to support our organ transplant\ncustomers.”\n\n“LPS clinicians will serve as preservationists in nearby surgical organ\nrecovery cases and can operate machine perfusion equipment,” said Christie\nCampbell, Strata’s VP of Cardiac Care. “This will make Strata an even more\nattractive partner to Transplant Centers and Organ Procurement\nOrganizations.”\n\n\"Our customers count on us to be there when it matters most and finding a\npartner who shares that commitment was my top priority,” said Herbie Eggers,\nCEO of Louisville Perfusion. “Strata's scale and clinical depth mean our\nhospital partners will see even stronger coverage and support, with the same\npeople and the same standard of service they already know.\"\n\n“Adding LPS to Strata's cardiac perfusion platform, which serves more than\n275 hospitals today, opens up new capabilities from expanded ECMO support to\nupgraded technology for the programs LPS serves, positioning the team to make\nan even bigger impact across the region for years to come,” said Melissa\nTomkiel, Co-CEO of Strata.\n\n“This all-cash acquisition is consistent with our M&A strategy of deploying\ncapital towards bolt-on acquisitions at accretive, mid-single digit Adjusted\nEBITDA multiples that both strengthen our existing service offerings and\nposition Strata for growth,” said Will Heyburn, Co-CEO and CFO of Strata.\n\nThe all-cash transaction consists of approximately $16 million upfront\nconsideration and up to $4 million additional consideration based on the\nfinancial performance of LPS in the 12 months following the transaction close.\nFor the full year 2026, LPS is expected to generate revenue and Adjusted\nEBITDA((1)) of approximately $10 million and $3 million, respectively, based\non LPS’s unaudited financial performance.\n\n(1) We have not reconciled the forward-looking Adjusted EBITDA guidance\nincluded above to the most directly comparable GAAP measure because this\ncannot be done without unreasonable effort due to the variability and low\nvisibility with respect to certain costs. We expect the variability of these\nitems to have a potentially unpredictable, and a potentially significant,\nimpact on our future GAAP financial results.\n\nAbout Strata Critical Medical, Inc.\n\nStrata is a time-critical logistics and medical services provider to the U.S.\nhealthcare industry. We operate one of the nation’s largest air transport\nand surgical services networks for transplant hospitals and organ procurement\norganizations, offering an integrated “one call” solution for donor organ\nrecovery.\n\nStrata’s core services include air and ground logistics, surgical organ\nrecovery, organ placement and normothermic regional perfusion for the\ntransplant industry, as well as perfusion staffing and equipment solutions for\ncardiovascular surgery centers, offered under the Trinity Medical Solutions\nand Keystone Perfusion brands.\n\nFor more information, visit https://stratacritical.com/.\n\nForward-Looking Statements\n\nThis press release contains “forward-looking statements” within the\nmeaning of the “safe harbor” provisions of the Private Securities\nLitigation Reform Act of 1995. Forward-looking statements include all\nstatements that are not historical facts and may be identified by the use of\nwords such as \"will\", “anticipate”, “believe”, “could”,\n“continue”, “expect\", “estimate”, “may”, “plan”,\n“outlook”, “future”, \"target\", and “project” and other similar\nexpressions and the negatives of those terms. These statements, which involve\nrisks and uncertainties, are based on forecasts of future results and\nestimates of amounts not yet determinable and may also relate to Strata’s\nfuture prospects, developments and business strategies. In particular, such\nforward-looking statements include statements concerning Strata’s future\nplans and business strategies, financial and operating performance (including\nthe discussion of financial outlook and guidance for 2026 and beyond),\nacquisition opportunities, results of operations, and industry environment and\ngrowth opportunities. These statements are based on management’s current\nexpectations and beliefs, as well as a number of assumptions concerning future\nevents. Actual results may differ materially from the results predicted, and\nreported results should not be considered as an indication of future\nperformance.\n\nSuch forward-looking statements are subject to known and unknown risks,\nuncertainties, assumptions and other important factors, many of which are\noutside Strata’s control, that could cause actual results to differ\nmaterially from the results discussed in the forward-looking statements.\nFactors that could cause actual results to differ materially from those\nexpressed or implied in forward-looking statements include: our continued net\nlosses or failure to achieve or maintain profitability; our ability to realize\nthe anticipated benefits of strategic transactions, including the recently\ncompleted divestment of the Passenger business and acquisition and integration\nof Keystone; any future acquisitions or partnerships; harm to our reputation\nand brand; negative publicity, litigation, claims or regulatory scrutiny; our\nability to provide high-quality customer support and maintain trusted\nrelationships with customers; our reliance on contractual relationships with\ntransplant centers, hospitals, Organ Procurement Organizations and strategic\npartners; adoption and effective utilization of our integrated clinical and\nlogistics offerings by medical customers; competition; our dependence on the\navailability and utilization of organ donors and transplant volumes;\ninsufficient reimbursement or funding for organ transport and related\nservices; risks inherent in organ transportation operations; risks associated\nwith ground transportation operations; advancements in preservation technology\nor alternative transport methods; aviation safety risks; the effects of\nclimate change, extreme weather events or environmental developments affecting\nour operations; terrorist attacks, geopolitical conflict or security events\naffecting aviation or healthcare infrastructure; the volatility in aircraft\nfuel availability or cost; our ability to obtain additional capital or\nfinancing; restrictions under our credit agreement; our ability to manage our\ngrowth; insurance market conditions; our dependence on key personnel and our\nability to attract and retain qualified professionals; employment-related\nclaims, workforce litigation or labor market challenges; our ability to\nmaintain our company culture as we grow; fluctuations in financial results and\nthe non-comparability of historical financial statements; risks associated\nwith purchasing aircraft or evolving from an asset-light model; risks\nassociated with directly operating aircraft; our reliance on maintaining\nefficient aircraft utilization to manage costs, operating efficiency and\nmargins; changes in regulatory frameworks; our reliance on third-party\naircraft operators; the availability of sufficient third-party aircraft\ncapacity; workforce disruptions, operations interruptions or financial\ndifficulties affecting third-party operators or service workers; risks arising\nfrom illegal, improper, or otherwise inappropriate operation of branded\naircraft by third-party operators; our reliance on third-party cloud\ninfrastructure, hosting providers and other technology vendors; interruptions,\ndefects, failures or vulnerabilities in our technology systems or those of\nthird-party providers; cybersecurity incidents, data breaches or misuse of\nartificial intelligence technologies; our ability to protect and enforce\nintellectual property rights; risks associated with our use of open-source\nsoftware; our operations within highly regulated environments; the impact of\nany litigation or regulatory investigations that we may be subject to; our\nability to comply with privacy, data protection, consumer protection and\nsecurity laws; the expansion of environmental regulations; our ability to\nremediate any material weaknesses and maintain effective disclosure controls\nand procedures; and other factors beyond our control. Additional factors can\nbe found in our most recent Annual Report on Form 10-K and Quarterly Report on\nForm 10-Q, each as filed with the U.S. Securities and Exchange Commission. New\nrisks and uncertainties arise from time to time, and it is impossible for us\nto predict these events or how they may affect us. You are cautioned not to\nplace undue reliance upon any forward-looking statements, which speak only as\nof the date made, and Strata undertakes no obligation to update or revise the\nforward-looking statements, whether as a result of new information, changes in\nexpectations, future events or otherwise.\n\nContacts\n\nMathew Schneider\ninvestors@srta.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/199716f4-aabd-4469-85e4-a085a6613ffe)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX7V3wxy","title":"Strata Acquires Louisville Perfusion Services","author":"Globe Newswire","ticker":"SRTA","created":"2026-06-02T13:00:03.844Z","tickers":["SRTA"],"exchange":"NASDAQ","article_body":"NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc.\n(Nasdaq: SRTA, “Strata” or the “Company”), today announced that it has\ncompleted the acquisition of Louisville Perfusion Services, Inc. (“LPS”),\na regional provider of perfusion and blood management services to cardiac\nsurgery programs in Kentucky.\n\n“The acquisition of Louisville Perfusion Services fits perfectly with our\nexisting customer base in Kentucky and Ohio, giving us a new strategic\nstronghold in the Midwest and Southern United States,” said Lou Verdetto,\nCEO of Strata’s Clinical Division. “More than just unlocking the ability\nto win new perfusion contracts in the region, LPS also expands the national\nfootprint of staff and equipment available to support our organ transplant\ncustomers.”\n\n“LPS clinicians will serve as preservationists in nearby surgical organ\nrecovery cases and can operate machine perfusion equipment,” said Christie\nCampbell, Strata’s VP of Cardiac Care. “This will make Strata an even more\nattractive partner to Transplant Centers and Organ Procurement\nOrganizations.”\n\n\"Our customers count on us to be there when it matters most and finding a\npartner who shares that commitment was my top priority,” said Herbie Eggers,\nCEO of Louisville Perfusion. “Strata's scale and clinical depth mean our\nhospital partners will see even stronger coverage and support, with the same\npeople and the same standard of service they already know.\"\n\n“Adding LPS to Strata's cardiac perfusion platform, which serves more than\n275 hospitals today, opens up new capabilities from expanded ECMO support to\nupgraded technology for the programs LPS serves, positioning the team to make\nan even bigger impact across the region for years to come,” said Melissa\nTomkiel, Co-CEO of Strata.\n\n“This all-cash acquisition is consistent with our M&A strategy of deploying\ncapital towards bolt-on acquisitions at accretive, mid-single digit Adjusted\nEBITDA multiples that both strengthen our existing service offerings and\nposition Strata for growth,” said Will Heyburn, Co-CEO and CFO of Strata.\n\nThe all-cash transaction consists of approximately $16 million upfront\nconsideration and up to $4 million additional consideration based on the\nfinancial performance of LPS in the 12 months following the transaction close.\nFor the full year 2026, LPS is expected to generate revenue and Adjusted\nEBITDA((1)) of approximately $10 million and $3 million, respectively, based\non LPS’s unaudited financial performance.\n\n(1) We have not reconciled the forward-looking Adjusted EBITDA guidance\nincluded above to the most directly comparable GAAP measure because this\ncannot be done without unreasonable effort due to the variability and low\nvisibility with respect to certain costs. We expect the variability of these\nitems to have a potentially unpredictable, and a potentially significant,\nimpact on our future GAAP financial results.\n\nAbout Strata Critical Medical, Inc.\n\nStrata is a time-critical logistics and medical services provider to the U.S.\nhealthcare industry. We operate one of the nation’s largest air transport\nand surgical services networks for transplant hospitals and organ procurement\norganizations, offering an integrated “one call” solution for donor organ\nrecovery.\n\nStrata’s core services include air and ground logistics, surgical organ\nrecovery, organ placement and normothermic regional perfusion for the\ntransplant industry, as well as perfusion staffing and equipment solutions for\ncardiovascular surgery centers, offered under the Trinity Medical Solutions\nand Keystone Perfusion brands.\n\nFor more information, visit https://stratacritical.com/.\n\nForward-Looking Statements\n\nThis press release contains “forward-looking statements” within the\nmeaning of the “safe harbor” provisions of the Private Securities\nLitigation Reform Act of 1995. Forward-looking statements include all\nstatements that are not historical facts and may be identified by the use of\nwords such as \"will\", “anticipate”, “believe”, “could”,\n“continue”, “expect\", “estimate”, “may”, “plan”,\n“outlook”, “future”, \"target\", and “project” and other similar\nexpressions and the negatives of those terms. These statements, which involve\nrisks and uncertainties, are based on forecasts of future results and\nestimates of amounts not yet determinable and may also relate to Strata’s\nfuture prospects, developments and business strategies. In particular, such\nforward-looking statements include statements concerning Strata’s future\nplans and business strategies, financial and operating performance (including\nthe discussion of financial outlook and guidance for 2026 and beyond),\nacquisition opportunities, results of operations, and industry environment and\ngrowth opportunities. These statements are based on management’s current\nexpectations and beliefs, as well as a number of assumptions concerning future\nevents. Actual results may differ materially from the results predicted, and\nreported results should not be considered as an indication of future\nperformance.\n\nSuch forward-looking statements are subject to known and unknown risks,\nuncertainties, assumptions and other important factors, many of which are\noutside Strata’s control, that could cause actual results to differ\nmaterially from the results discussed in the forward-looking statements.\nFactors that could cause actual results to differ materially from those\nexpressed or implied in forward-looking statements include: our continued net\nlosses or failure to achieve or maintain profitability; our ability to realize\nthe anticipated benefits of strategic transactions, including the recently\ncompleted divestment of the Passenger business and acquisition and integration\nof Keystone; any future acquisitions or partnerships; harm to our reputation\nand brand; negative publicity, litigation, claims or regulatory scrutiny; our\nability to provide high-quality customer support and maintain trusted\nrelationships with customers; our reliance on contractual relationships with\ntransplant centers, hospitals, Organ Procurement Organizations and strategic\npartners; adoption and effective utilization of our integrated clinical and\nlogistics offerings by medical customers; competition; our dependence on the\navailability and utilization of organ donors and transplant volumes;\ninsufficient reimbursement or funding for organ transport and related\nservices; risks inherent in organ transportation operations; risks associated\nwith ground transportation operations; advancements in preservation technology\nor alternative transport methods; aviation safety risks; the effects of\nclimate change, extreme weather events or environmental developments affecting\nour operations; terrorist attacks, geopolitical conflict or security events\naffecting aviation or healthcare infrastructure; the volatility in aircraft\nfuel availability or cost; our ability to obtain additional capital or\nfinancing; restrictions under our credit agreement; our ability to manage our\ngrowth; insurance market conditions; our dependence on key personnel and our\nability to attract and retain qualified professionals; employment-related\nclaims, workforce litigation or labor market challenges; our ability to\nmaintain our company culture as we grow; fluctuations in financial results and\nthe non-comparability of historical financial statements; risks associated\nwith purchasing aircraft or evolving from an asset-light model; risks\nassociated with directly operating aircraft; our reliance on maintaining\nefficient aircraft utilization to manage costs, operating efficiency and\nmargins; changes in regulatory frameworks; our reliance on third-party\naircraft operators; the availability of sufficient third-party aircraft\ncapacity; workforce disruptions, operations interruptions or financial\ndifficulties affecting third-party operators or service workers; risks arising\nfrom illegal, improper, or otherwise inappropriate operation of branded\naircraft by third-party operators; our reliance on third-party cloud\ninfrastructure, hosting providers and other technology vendors; interruptions,\ndefects, failures or vulnerabilities in our technology systems or those of\nthird-party providers; cybersecurity incidents, data breaches or misuse of\nartificial intelligence technologies; our ability to protect and enforce\nintellectual property rights; risks associated with our use of open-source\nsoftware; our operations within highly regulated environments; the impact of\nany litigation or regulatory investigations that we may be subject to; our\nability to comply with privacy, data protection, consumer protection and\nsecurity laws; the expansion of environmental regulations; our ability to\nremediate any material weaknesses and maintain effective disclosure controls\nand procedures; and other factors beyond our control. Additional factors can\nbe found in our most recent Annual Report on Form 10-K and Quarterly Report on\nForm 10-Q, each as filed with the U.S. Securities and Exchange Commission. New\nrisks and uncertainties arise from time to time, and it is impossible for us\nto predict these events or how they may affect us. You are cautioned not to\nplace undue reliance upon any forward-looking statements, which speak only as\nof the date made, and Strata undertakes no obligation to update or revise the\nforward-looking statements, whether as a result of new information, changes in\nexpectations, future events or otherwise.\n\nContacts\n\nMathew Schneider\ninvestors@srta.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/199716f4-aabd-4469-85e4-a085a6613ffe)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-02T13:00:04.012201821Z","server_sent_at_ms":1780405204012},"received_at":"2026-06-02T13:00:04.246Z","source_url":null},"analysis":{"id":"41776","press_release_id":"52346","analysis_json":{"industry":{"label":"Health Care Providers & Services","sector":"Health Care"},"redFlags":[],"eventType":"m_and_a","narrative":"Strata Critical Medical completed the all-cash acquisition of Louisville Perfusion Services (LPS), a regional provider of perfusion and blood management services in Kentucky.\n\nThe transaction involves approximately $16 million in upfront consideration plus up to $4 million in earnout payments based on LPS’s financial performance over the next 12 months.\n\nManagement stated the deal is accretive, priced at mid-single-digit Adjusted EBITDA multiples, and expands Strata’s national footprint for organ transplant and cardiac surgery support.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Strata executes another accretive bolt-on M&A deal, expanding its perfusion and transplant logistics footprint in the Midwest."},"keyFigures":{"dealValueUsd":20000000,"customDimensions":{"earnout_potential":4000000,"target_ebitda_2026":3000000,"target_revenue_2026":10000000,"hospital_count_served":275,"upfront_consideration":16000000}},"quotedText":"This all-cash acquisition is consistent with our M&A strategy of deploying capital towards bolt-on acquisitions at accretive, mid-single digit Adjusted EBITDA multiples that both strengthen our existing service offerings and position Strata for growth","namedEntities":{"people":[{"name":"Lou Verdetto","role":"CEO of Strata’s Clinical Division"},{"name":"Christie Campbell","role":"VP of Cardiac Care"},{"name":"Herbie Eggers","role":"CEO of Louisville Perfusion"},{"name":"Melissa Tomkiel","role":"Co-CEO of Strata"},{"name":"Will Heyburn","role":"Co-CEO and CFO of Strata"},{"name":"Mathew Schneider","role":"Investor Relations Contact"}],"products":["Trinity Medical Solutions","Keystone Perfusion"],"companies":[{"name":"Strata Critical Medical, Inc.","ticker":"SRTA","relationship":"acquirer"},{"name":"Louisville Perfusion Services, Inc.","relationship":"target"}],"dollarAmounts":[{"amount":"$16 million","context":"upfront acquisition consideration"},{"amount":"$4 million","context":"additional earnout consideration"},{"amount":"$10 million","context":"LPS expected FY2026 revenue"},{"amount":"$3 million","context":"LPS expected FY2026 Adjusted EBITDA"}]},"materialImpact":{"score":3,"reasoning":"Strata completed a bolt-on acquisition of Louisville Perfusion Services for ~$20M total consideration. The deal is accretive (mid-single digit EBITDA multiple) and expands the company's footprint in the Midwest/South, but the size is modest relative to the company's overall operations."},"tickerRelevance":{"others":[],"primary":"SRTA"},"globalImportance":25,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"bolt-on acquisition","sectorWeight":"moderate","householdBrandBoost":0,"marketCapAdjustment":"low","retailFavoriteBoost":0}},"event_type":"m_and_a","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Strata Critical Medical completed the all-cash acquisition of Louisville Perfusion Services (LPS), a regional provider of perfusion and blood management services in Kentucky.\n\nThe transaction involves approximately $16 million in upfront consideration plus up to $4 million in earnout payments based on LPS’s financial performance over the next 12 months.\n\nManagement stated the deal is accretive, priced at mid-single-digit Adjusted EBITDA multiples, and expands Strata’s national footprint for organ transplant and cardiac surgery support.","key_figures":{"dealValueUsd":20000000,"customDimensions":{"earnout_potential":4000000,"target_ebitda_2026":3000000,"target_revenue_2026":10000000,"hospital_count_served":275,"upfront_consideration":16000000}},"named_entities":{"people":[{"name":"Lou Verdetto","role":"CEO of Strata’s Clinical Division"},{"name":"Christie Campbell","role":"VP of Cardiac Care"},{"name":"Herbie Eggers","role":"CEO of Louisville Perfusion"},{"name":"Melissa Tomkiel","role":"Co-CEO of Strata"},{"name":"Will Heyburn","role":"Co-CEO and CFO of Strata"},{"name":"Mathew Schneider","role":"Investor Relations Contact"}],"products":["Trinity Medical Solutions","Keystone Perfusion"],"companies":[{"name":"Strata Critical Medical, Inc.","ticker":"SRTA","relationship":"acquirer"},{"name":"Louisville Perfusion Services, Inc.","relationship":"target"}],"dollarAmounts":[{"amount":"$16 million","context":"upfront acquisition consideration"},{"amount":"$4 million","context":"additional earnout consideration"},{"amount":"$10 million","context":"LPS expected FY2026 revenue"},{"amount":"$3 million","context":"LPS expected FY2026 Adjusted EBITDA"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-02T13:08:13.317Z","global_importance":25,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"bolt-on acquisition","sectorWeight":"moderate","householdBrandBoost":0,"marketCapAdjustment":"low","retailFavoriteBoost":0}},"durationMs":84044,"modelName":"george-droid-qwen-72b"}}